POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) AFTER SOLID ORGAN TRANSPLANTATION

PTLD is a rare complication that can arise after solid organ transplantation (SOT) and is often associated with very poor outcomes. It can occur due to the immune suppression following transplant. The primary cause of PTLD is the Epstein-Barr virus (EBV) which remains in a latent state with a normal immune system but becomes active when the immune system is suppressed.1

THIS FACT SHEET COVERS:
- Standard treatment for PTLD
- A Phase 3 clinical trial for PTLD, including eligibility and contact information
- Resources to help patients pay for clinical trial travel related costs

STANDARD TREATMENT

Initial treatment typically includes:
- Reduction of immunosuppression to see if the patient’s own immune system can fight the PTLD.
- Rituximab (Rituxan®) to target the patient’s B cells.
- If the PTLD is unresponsive to rituximab or is highly aggressive, chemotherapy may be employed.
- Other treatments in development, available through clinical trials.1

The Food and Drug Administration (FDA) has not yet approved any therapies to treat PTLD.

Support for this publication provided by:

References:

CELLULAR THERAPY CLINICAL TRIAL

Title: Tabelecleucel (tab-cel™) to treat EBV-associated PTLD after solid organ transplant – (NCT03394365)

Type: Multicenter, open label, single-arm, phase 3 trial

Goal: To assess the efficacy and safety of tabelecleucel for the treatment of Epstein-Barr Virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of SOT after failure of rituximab or rituximab plus chemotherapy.

Who can join: Patients who have:
- EBV-positive PTLD after solid organ transplant (liver, kidney, heart, lung, pancreas, small bowel or any combination of these)
- PTLD after failure of rituximab with or without chemotherapy; CD20 negative PTLD is eligible after failure of first line chemotherapy
- A suitably matched tab-cel product available
- Adequate organ function and blood counts as defined by the trial protocol

Treatments: Tab-cel is made with T cells from a healthy donor. Expanded, genetically unmodified donor EBV-directed T cells may find and destroy the patient’s EBV-infected B cells. Tab-cels is given as an IV infusion on days 1, 8, and 15 of every 5-week cycle. Infusion can be done as inpatient or outpatient and requires monitoring of vitals for 2 hours post-infusion. Treatment continues until maximal response with up to 4 different tab-cel products, unacceptable toxicity, or initiation of non-protocol therapy.

Sponsor: Atara Biotherapeutics

Study Directors:
Willis H Navarro, MD Akshay Sudhindra, MD Atara Biotherapeutics Tel (805) 603-4856
Email: clinicaltrials@atarabio.com
Tabelecleucel Trial Locations:

United States, California
University of California Davis Comprehensive Cancer Center (Adults only)
Sacramento, California, United States, 95817
Contact: Mehrdad Abedi, MD  916-703-9118
mabedi@ucdavis.edu

United States, Connecticut
Yale University (Adults and Pediatrics)
New Haven, Connecticut, United States, 06519
Contact: Pamela Valentino, MD  203-785-4649
pamela.valentino@yale.edu

United States, District of Columbia
Lombardi Comprehensive Cancer Center (Adult and Pediatrics)
Washington, District of Columbia, United States, 20017
Contact: Corina Gonzalez, MD  202-444-2224
corina.gonzalez@medstar.net

United States, Florida
University of Florida (Adults and Pediatrics)
Gainesville, Florida, United States, 32610
Contact: John Fort, MD  352-273-9120
jonfort@ufl.edu
Leonard M. Miller School of Medicine - Miami Transplant Institute (Adults only)
Miami, Florida, United States, 33136
Contact: Amer Beitinjaneh, MD, MPH, MSc  305-243-6626
abeitinjaneh@miami.edu

United States, Georgia
Winship Cancer Institute of Emory University (Adults only)
Atlanta, Georgia, United States, 30322
Contact: Jonathon Cohen, MD  404-778-3942
jonathon.cohen@emory.edu

United States, Illinois
Loyola University Medical Center (Adults and Pediatrics)
Maywood, Illinois, United States, 60153
Contact: Patrick Stiff, MD  708-327-3148
pstiff@lumc.edu

United States, Indiana
Washington University School of Medicine (Adults only)
Saint Louis, Missouri, United States, 63110
Contact: Armin Ghabadi, MD  314-747-8439
arminghabadi@wustl.edu

United States, New York
Montefiore Medical Center (Adults only)
Bronx, New York, United States, 10467
Contact: David Loeb, MD, PhD  718-741-2342
dloeb@montefiore.org
Montefiore Medical Center (Pediatrics only)
Bronx, New York, United States, 10467
Contact: Ran Reshef, MD  212-342-0530
rr3036@cumc.columbia.edu
Memorial Sloan Kettering Cancer Center (Adults and Pediatrics)
New York, New York, United States, 10065
Contact: Susan Prockop, MD  212-639-6715
prockops@mskcc.org

GRANTS FOR CLINICAL TRIAL TRAVEL COSTS

The Drs. Jeffrey and Isabel Chell Clinical Trials Travel Grant helps qualified patients pay for travel expenses for eligible clinical trials, including the trial described here.
- **Call:** (888) 814-8610
- **Email:** clinicaltrials@JCCTP.org
- **Visit:** JCCTP.org